Bigfoot Biomedical has been granted a patent for a pen cap for an insulin pen that includes a monitoring feature. The cap has a user interface to display therapy information and recommendations, and a controller to detect when the cap is capped or uncapped. If the cap is capped for a certain period of time, the user interface will display a recommended correction dose of insulin based on insulin sensitivity and target glucose levels. GlobalData’s report on Bigfoot Biomedical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Bigfoot Biomedical, Wearable drug delivery devices was a key innovation area identified from patents. Bigfoot Biomedical's grant share as of September 2023 was 33%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for a monitoring pen cap for insulin pen
A recently granted patent (Publication Number: US11771835B2) describes a pen cap for an insulin pen that includes a user interface to display therapy relevant information, therapy recommendations, or the time of capping or decapping the pen cap. The pen cap also includes a controller with a processor and computer-readable storage medium. When the pen cap is capped on the insulin pen for a specific period of time, the controller displays a recommended correction dose of insulin based on factors such as insulin sensitivity and target glucose levels.
The pen cap can be used with either a long-acting insulin pen or a rapid-acting insulin pen. It also includes instructions for receiving glucose data, allowing the user to monitor their glucose levels. The pen cap features a communication interface that generates two wireless signals, with the second signal having a larger communication range than the first. The first signal is designed to communicate with a glucose monitor within its range, while the second signal can communicate with a glucose monitor or another remote device.
The controller can automatically communicate with a glucose monitor or another remote device via the second wireless signal. The communication interface includes at least one wireless radio. Additionally, the pen cap can detect a glucose monitor within the range of the first wireless signal and communicate with it using a near field communication protocol.
The pen cap can also communicate with a glucose sensor system that includes a flash glucose monitor. It has the capability to display the percentage of active insulin remaining in the user based on the time of the previous capping or decapping of the pen cap and the current time. The controller can estimate the amount of active insulin remaining based on the current time and the time and dose amount associated with the previous capping or decapping.
Another embodiment of the pen cap includes a motion detection feature. When the pen cap remains motionless for a specific period of time, the user interface displays a recommended correction dose of insulin based on the insulin sensitivity factor and target glucose value stored in memory. This feature helps users manage their insulin dosage effectively.
In summary, this patent describes a pen cap for insulin pens that provides therapy information, recommendations, and glucose monitoring capabilities. It includes wireless communication features and can display the remaining active insulin and recommended correction doses based on various factors. The motion detection feature enhances insulin delivery management.